Oral Cefixime is beneficial in acute uncomplicated Salmonella gastroenteritis in children with mucoid or bloody diarrhea – Do indications of antibiotics therapy need reassessment?  by Lee, H.-Y. et al.
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harmacodynamic proﬁling of intravenous antibiotics
gainst gram-negative bacteria collected during the Track-
ng Resistance in the United States Today (TRUST)
urveillance program
. Koomanachai, D.P. Nicolau ∗, J.L. Kuti, C.C. Bulik
Hartford Hospital, 06106, CT, USA
Background: Antibiotic resistance in Gram-negative bac-
illi (GNB) is escalating globally; thus achieving optimal
ntimicrobial exposures has become considerably more
hallenging. We used data from ‘‘Tracking Resistance in
he United States Today (TRUST) surveillance program’’ to
ompare the probabilities of attaining requisite antibiotic
xposures against Escherichia coli, Klebsiella pneumoniae,
cinetobacter baumannii, and Pseudomonas aeruginosa.
Methods: Using Monte Carlo simulation, pharma-
odynamic proﬁling was performed for standard and
rolonged infusions of cefepime 1&2gq12 h, 2gq8h(0.5h&3h
nfusions); ceftazidime 1&2gq8h(0.5&3 h); ceftriax-
ne; 1&2gq24h(0.5 h); ciproﬂoxacin 0.4gq8&12h(1 h);
oripenem 0.5, 1&2gq8h(1&4 h); ertapenem 1gq24h(0.5 h);
mipenem 0.5gq6&8h(0.5 h), 1gq8h(0.5&3 h); lev-
ﬂoxacin 0.75gq24h(1 h); meropenem 0.5gq6&8h(0.5 h)
hen 1&2gq8h(0.5&3 h); piperacillin/tazobactam
.375&4.5gq6h(0.5 h), 3.375gq8h(4 h), 4.5gq6h(3 h).
IC data were incorporated from the 2008 TRUST program.
harmacodynamic targets were deﬁned as fT>MIC >40% for
arbapenems, 50% for penicillins and cephalosporins. A
otal AUC/MIC ≥87 and ≥125 was applied for levoﬂoxacin
nd ciproﬂoxacin, respectively. The cumulative fraction of
esponse (CFR) was determined for each regimen against
ach population of organisms. Optimal CFR was deﬁned a
riori as ≥90%.
Results: The ﬂuoroquinolones displayed the lowest sus-
eptibilities against all organisms. All cephalosporins, car-
apenems and piperacillin/tazobactam had susceptibility
ates >90% for Enterobacteriaceae. Against P. aerugi-
osa, piperacillin/tazobactam portrayed the highest per-
ent susceptibility(90%), followed by meropenem(89.8%),
efepime(88%), and ceftazidime/doripenem(86%). All $-
actam regimens achieved optimal CFR against E. coli,
nd all but piperacillin/tazobactam 3.375 g q6h achieved
ptimal CFR against K. pneumoniae. The ﬂuoroquinolones
chieved the lowest CFRs against all organisms. Against P.
eruginosa, high dose, prolonged infusion doripenem and
eropenem achieved CFRs of 97.2% to 98.8%, followed
y high dose, prolonged infusion ceftazidime(93.3%) and
efepime(93.2%). No regimens achieved optimal CFR against
. baumannii. Prolonged infusion regimens increased CFR for
ll $-lactams against the non-fermenting GNB.
Conclusion: Standard intravenous doses of many com-
only $-lactam regimens have a high probability of
chieving optimal exposure against Enterobacteriaceae. For
on-fermenting-GNB, higher dose, prolonged infusions of
efepime, ceftazidime, doripenem, and meropenem offered
he highest probabilities of achieving bactericidal exposure.
oi:10.1016/j.ijid.2010.02.1922
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ral Ceﬁxime is beneﬁcial in acute uncomplicated
almonella gastroenteritis in children with mucoid or
loody diarrhea — Do indications of antibiotics therapy
eed reassessment?
.-Y. Lee1,∗, T.-Y. Lin2, C.-T. Wu3, C.-H. Chiu3, Y.-C. Huang3
Chang Gung Memorial Hospital and Chang Gung University,
weishan, Taoyuan, Taiwan, R.O.C
Chang-Gung Memorial Hospital, Linkou, Taiwan, R.O.C
Taoyuan, China
Background: Conventional antibiotics not only pro-
ided no beneﬁt to pediatric patients with uncomplicated
almonella enterocolitis but also increased the rate of
elapse and duration of fecal excretion. This study was
esigned to evaluate the role of ceﬁxime, an oral
ephalosporine with excellent activity against Salmonella,
n the treatment of uncomplicated nontyphoid Salmonella
nteritis in children.
Methods: In a randomized, prospective, double-blind,
wo-center study, children with uncomplicated Salmonella
astroenteritis and mucoid/bloody diarrhea were treated
ith oral ceﬁxime (10mg/kg/day divided twice daily) or
lacebo for 5 days. There was no signiﬁcant difference
etween these two groups in their characteristics, sever-
ty of disease and distributions of serogroups (Table 1). The
uration of fever and diarrhea were recorded by hours. Stool
amples were sent for culture weekly until three consecutive
egative results were obtained. Subsequent follow-up visits
ere at any time when diarrhea happened or at two-week
ntervals for the ﬁrst two months, three-month interval for
he following one year and two-year interval for the follow-
ng six years.
Results: Sixty-eight patients with acute, uncompli-
ated culture-proved Salmonella enteritis were enrolled.
erogroup B was the most commonly isolated serogroup
n both oral ceﬁxime group and placebo group (26/37,
4/31), followed by serogroup C (6/37, 3/31) and D
4/37, 4/31). The susceptibility rate of ceﬁxime in vitro
100%) was equal to that of ceftriaxone (100%), and
igher than those of ciproﬂoxacin (97.06%), ceftizoxime
97.06%), sulfamethoxazole-trimethoprim (51.47%), ampi-
illin (42.65%), and chloramphenicol (41.18%).The duration of diarrhea or mucoid diarrhea was signif-
cantly reduced by antibiotic treatment (mean 55.8 hours
s 79.2 hours, p = 0.009; 49.5 hours vs 73.0 hours, p = 0.036)
Table 2). Time to defervescence was signiﬁcantly short-
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ened in the group receiving ceﬁxime (mean 15.0 hours vs
29.3 hours, p = 0.028). However, there was no signiﬁcant dif-
ference with respect to the rate of clearance of Salmonella
from stool (p = 0.843). All followed-up samples after com-
pleting therapy, remained sensitive in vitro to ceﬁxime.
There was no relapse of the same pathogen found.
Conclusion: The clinical trial showed that ceﬁxime could
shorten the time to defervescence and the duration of
diarrhea signiﬁcantly. Prolonging the period of carriage or
increasing the risk of relapse was not found in this study.
Ceﬁxime could be considered in acute, uncomplicated,
Salmonella enteritis in children with mucoid/bloody diar-
rhea.
doi:10.1016/j.ijid.2010.02.1923
49.007
Evaluation of the pharmacodynamics of Daptomycin
(DAP)-Rifampin (RIF) combinations with Staphylococcus
aureus using various in vitro methods
S. Zinner1,∗, M. Smirnova2, E. Strukova2, A. Firsov2
1 Mount Auburn Hospital, Harvard Medical School, MA, MA,
USA
2 Gause Institute for Antibiotics, Moscow, Russian Federa-
tion
Background: The evaluation of antibiotic combinations
is often based on traditional checkerboard techniques (CT)
that might or might not provide optimal interpretations. In
this study, DAP plus RIF combinations were tested with S.
aureus using CT as well as time-kill curves at constant and
changing antibiotic concentrations – static studies (SS) and
dynamic studies (DS), respectively.
Methods: A clinical isolate S. aureus 866 (MIC of DAP
0.5mg/L, MIC of RIF 0.016mg/L) was tested using CT at DAP
concentrations ranging from 0 to 2mg/L and RIF concentra-
tions ranging from 0 to 0.06mg/L. In SS, the same organism
was exposed to DAP (0.5, 1, 2, 4, 8 and 6mg/L), alone and in
combination with RIF (DAP/RIF 1:1.5) over a 24-hour period.
In DS, S. aureus was exposed to daily administered DAP and
DAP+RIF for 5 consecutive days; the simulated ratios of area
under concentration-time curve (AUC) to the MIC were 50
and 50+75, respectively. The antimicrobial effects observed
in SS and DS were expressed by areas between the bacte-
rial concentration — time curves with and without antibiotic
(ABBCs).
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Results: Based on the CT data, DAP+RIF combinations
ere additive or indifferent (FIC index = 1). Based on ABBC
nalysis of the SS data, DAP+RIF was synergistic at relatively
ow AUC/MICs of DAP (24-96) or additive at higher AUC/MICs
f DAP (192-770). For example, the 24-hour ABBC of DAP
AUC/MIC 48) + RIF (AUC/MIC 72) was 9-fold greater than
hat of DAP (AUC/MIC 48). Similar differences in the effects
f DAP+RIF and DAP were established in DS: the 120-hour
BBC was 13 times greater in simulations of the combination
han DAP alone.
Conclusion: These data suggest that (1) checker-
oard technique-based evaluations of daptomycin+rifampin
ombinations can be misleading, and (2) in vitro pharmaco-
ynamic data obtained in static systems are predictive of
hose in dynamic studies.
oi:10.1016/j.ijid.2010.02.1924
9.008
he effectiveness of oral suppression in high risk pros-
hetic joint infections after total knee arthroplasty
. McBroom1,∗, D.J. Barbaro2
University of North Texas Health Science Center, Fort
orth, TX, USA
Tarrant County Infectious Disease Associates, Fort Worth,
X, USA
Background: Prosthetic joint infection (PJI) is a rare but
erious complication of total knee arthroplasty (TKA) and is
frequent reason for failure to retain the prosthesis. Recent
tudies have reported success rates of >80 percent with
ebridement and retention of prosthesis between 2 to 5-year
ollow-up periods. Lack of consensus on deﬁnitions of PJI
nd risk factors between centers makes evaluation of true
isk factors and outcomes a challenge. Though improved suc-
ess rates have been reported for the conservative approach
f debridement, intravenous (IV) antimicrobial therapy, and
rosthesis retention, little data exists on combining the use
f oral suppressive therapy with this treatment option.
Methods: Nine year retrospective study of 28 high risk PJI
atients after TKA who had been treated with debridement,
ix weeks IV antimicrobial therapy and prosthesis retention,
r the same treatment with oral suppressive therapy and had
two to ﬁve year follow-up to ascertain the effectiveness
f oral suppressive therapy, excluding potential confound-
ng factors such as chemotherapy, HIV treatment, or steriod
herapy. Statististical analysis involved estimation of cumu-
ative probability of treatment failure using Kaplan Meier
ethod and total curve comparison was obtained by using
he Mantel-Cox logrank method. Fisher’s exact test and the
ilcoxon rank sum test were used for univariate analysis.
Results: The 2-year cumulative probability of failure for
ral suppressive therapy was 7% (95% CI: 0.04 to 27.5)
ompared to 42% (95% CI: 17.7 to 66.07) for the control
roup. Oral suppressive therapy was signiﬁcantly differ-
nt than control (P = 0.033).Conclusion: Treating high risk
atients with only six weeks IV antimicrobial therapy and
ebridement, especially in early postoperative infections,
ould lead to treatment failure sooner than when treating
atients with oral suppressive therapy. The effectiveness
f this treatment could reﬂect the importance of using
